FDA commish: First Amendment DTC defense airtight

Share this article:
FDA commissioner Andrew von Eschenbach issued a staunch First Amendment defense of DTC advertising at last week’s Center for Medicine in the Public Interest conference in Washington, DC. Asked his view on the controversy over DTC and the prospects of legislative tinkering with advertising regulation, von Eschenbach said: “As with any particular entity, whether an organization or individual, there is a right to free speech and an ability under the Constitution to free expression. We need to make sure the content is factual and accurate. FDA has role in making sure the public is continuing to get correct information.”
Share this article:

Email Newsletters

More in News

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.

Five things for pharma marketers to know: Thursday, August 21

Five things for pharma marketers to know: Thursday, ...

An Ebola survivor is set to leave Emory University Hospital, but the cause of the cure is uncertain, the FDA has approved a new type 1 diabetes test, and the ...